<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829749</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0115</org_study_id>
    <nct_id>NCT02829749</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Mitral Valve Repair With the NeoChord DS1000 Artificial Chordae Delivery System Versus Conventional Surgery in Patients With Severe Primary Mitral Regurgitation Due to Isolated Leaflet Prolapse</brief_title>
  <acronym>MITRACHORD</acronym>
  <official_title>A European, Multicenter, Randomized Study Comparing the Effectiveness and Safety of Mitral Valve Repair With the NeoChord DS1000 Artificial Chordae Delivery System Versus Conventional Surgery in Patients With Severe Primary Mitral Regurgitation Due to Isolated Leaflet Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to assess the effectiveness and safety of the NeoChord DS1000 repair
      technique as compared with conventional open-heart on-pump mitral valve surgery in patients
      with severe primary mitral regurgitation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined incidence of Death from any cause, redo surgery for valve dysfunction, and moderate-severe (3+) or severe (4+) mitral regurgitation</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with any major adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Major adverse events defined by death all cause, Post-operative myocardial infarction, Reoperation for failed surgical repair or valve replacement, Any reoperation or intervention for adverse events (Bleeding…), stoke, renal failure, wound infection, septicemia, ventilation &gt; 24 hours, transfusion ≥ 2 units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral valve reoperation free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mitral regurgitation &gt; 2+</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from rehospitalization for heart failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional evaluation (NYHA)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functional evaluation (6 minute walk test )</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life score</measure>
    <time_frame>12 months</time_frame>
    <description>by using the EQ-5D questionnaire ( European Quality of Life-5 Dimensions) instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of device success</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>NeoChord DS1000 Artificial Chordae Delivery System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the experimental group will undergo the NeoChord implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>traditional mitral valve repair performed under cardiac arrest</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeoChord beating heart mitral valve implantation</intervention_name>
    <description>The NeoChord DS1000 procedure is performed in five steps: (1) Device Preparation; (2) Left Ventricular Access; (3) Leaflet Capture and Verification; (4) Suture Deployment and (5) Suture Closure. The sutures are placed via a ventriculotomy 2-4 cm postero-lateral from the apex of the left ventricle via thoracotomy. The procedure is performed on a beating heart through a 2 to 3 inch right antero-lateral thoracotomy, then one to five Goretex neochordae are introduced with a transcatheter delivery system through the apex of the heart, into the left ventricle, and fixed on the free edge of the prolapsed leaflet. This is performed with transesophageal echocardiographic guidance.</description>
    <arm_group_label>NeoChord DS1000 Artificial Chordae Delivery System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>traditional mitral valve repair performed under cardiac arrest</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe primary mitral regurgitation (grade 3+ or 4+)

          -  Class I indication for MV Surgery according to ESC/EACTS and AHA/ACC guidelines:

               1. Symptomatic patients and/or

               2. LV (Left Ventricular) dysfunction : LVESD ≥45 mm and/or 30≤ LVEF ≤60%

          -  Leaflet prolapse of P2 and/or A2

          -  Predicted coaptation length &gt; 4 mm

          -  Candidates for surgical mitral valve repair according to heart team

          -  Patient able to sign an informed consent form

          -  Patient benefiting from a social insurance system or a similar system

        Exclusion Criteria:

          -  Asymptomatic patients with preserved LV function

          -  Complex mechanism of MR (leaflet perforation, severe calcifications, commissural
             extension, etc)

          -  Secondary MR

          -  Predicted post-repair coaptation length less than 4 mm

          -  Atrial fibrillation

          -  Inflammatory or infective valve disease

          -  Severe LV dilation (DTD &gt; 65 mm)

          -  Significant mitral annulus dilatation (D &gt; 45 mm)

          -  Surgical indication of tricuspid annulus

          -  Contraindication to TEE (transesophageal echocardiographic ) or inadequate image
             quality

          -  Need for any other concomitant cardiac procedure

          -  Concurrent medical condition with a life expectancy of less than 24 months

          -  Patient unable to understand the purpose of the trial

          -  Patient &lt; 18 years old

          -  Participation to another trial that would interfere with this trial

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-François OBADIA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-François OBADIA, MD</last_name>
    <phone>4 72 35 72 47</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-francois.obadia@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathan MEWTON, MD</last_name>
    <phone>4 27 85 66 87</phone>
    <email>nathan.mewton@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François Obadia, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Valve Diseases</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Heart diseases</keyword>
  <keyword>Mitral valve insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

